The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab.
Jennifer L. Wayne
No relevant relationships to disclose
Kristen N. Ganjoo
No relevant relationships to disclose
Brad L. Pohlman
No relevant relationships to disclose
Sven De Vos
No relevant relationships to disclose
Ian W. Flinn
No relevant relationships to disclose
Nam H. Dang
No relevant relationships to disclose
Markus Y. Mapara
No relevant relationships to disclose
Mitchell R. Smith
No relevant relationships to disclose
Adrienne M. O'Reilly
No relevant relationships to disclose
Shashidhara Y. Marulappa
No relevant relationships to disclose
Vinay Kumar Jain
No relevant relationships to disclose